The Californer - Xycota Biosciences Announces Nature Portfolio Publication Supporting Brain Repair Platform Targeting FTD and ALS

Trending...

Eric Bellinger Debuts "Cry In Front Of You" Live Following Tamla Motown Signing
Rabbi Michael Rothschild (#ViralRabbi) to Discuss Futurism on the Popular "The Mike Holt Show"
On the 296th Anniversary of the Ceremony That Made His Ancestor Emperor, a Cherokee Descendant Publishes the Novel That Restores Him

BEVERLY HILLS, Calif. - Californer -- Xycota Biosciences, LLC ("Xycota"), an early-stage biotechnology company focused on brain repair therapeutics, today announced the formal unveiling of its neuro-restoration platform, anchored by newly published mechanistic evidence in the Nature Portfolio journal Neuropsychopharmacology.

The paper, "Psilocybin improves novel object recognition... through the modulation of the BDNF/TrkB signaling pathway" (Trezza, Hausman, et al., 2026), provides mechanistic evidence supporting the company's brain repair strategy: restoring synaptic function and neural circuitry by decoupling therapeutic effects from psychedelic receptor activity.

The "Big Unlock": Mechanistic Insight into Neural Repair

For decades, the therapeutic potential of psilocybin was assumed to be inseparable from its psychedelic effects. The Trezza-Hausman findings provide a strong translational rationale for challenging this paradigm. The research suggests that cognitive restoration may be mediated primarily through the BDNF/TrkB signaling pathway—the brain's intrinsic growth and repair circuitry—rather than hallucinogenic receptor pathways.

More on The Californer

"This discovery is the bedrock of Xycota," said Dr. Marvin S. Hausman, MD, Founder and CSO. "We have identified a biological signaling pathway that triggers neural repair. Xycota was formed to translate this insight into a standardized biological interface, allowing us to engineer restorative therapeutics without the psychedelic effects."

The FTD-ALS Continuum: A Strategic Clinical Roadmap

With the BDNF-TrkB mechanism supported by preclinical data, Xycota is focusing its primary development program on Frontotemporal Dementia (FTD). FTD is a catastrophic condition characterized by the progressive decay of synaptic connections, leading to the loss of judgment, personality, and cognitive independence.

Strategically, Xycota's focus on FTD provides a critical entry point into a broader spectrum of neurodegenerative disorders. FTD and Amyotrophic Lateral Sclerosis (ALS) are increasingly recognized as part of a clinical and pathological continuum, often sharing underlying synaptic vulnerabilities and protein pathologies. By establishing a translational signal of repair in FTD, Xycota plans to expand its platform to address the urgent unmet needs in ALS and other disorders where synaptic degeneration is a primary driver of decay.

More on The Californer

Technology: Fungal-Derived Exosome Delivery

To translate these findings into a clinical reality, Xycota is developing a proprietary fungal-derived exosome delivery platform. This biological delivery vehicle is being engineered to improve CNS targeting and blood-brain barrier penetration, allowing for liver-bypass and more precise modulation of the BDNF pathway.

"Our goal is to move medicine from symptom management to the restoration of synaptic function," said Brad Listermann, President & Co-Founder. "By merging Dr. Hausman's 50-year track record in CNS development with this mechanistic evidence, Xycota is built to deliver a measurable signal of brain repair across multiple CNS disorders."

About Xycota Biosciences, LLC

Xycota Biosciences is an early-stage biotechnology company developing precision neuroplasticity therapeutics. Anchored by peer-reviewed science in the Nature Portfolio (Neuropsychopharmacology and npj Aging), Xycota is building a scalable translational platform to treat FTD, ALS, and mTBI through targeted synaptogenesis and neural repair.

For more information or to access the Strategic Data Room, visit https://xycota.com.